Efficacy and Safety of Uronext® in Women With Cystitis

PharmaLinea

Status: Completed

Conditions: Cystitis

Treatments: Drug: Monural; Dietary Supplement: UroNext

Study type: Interventional

Funder types: Industry; Other

Identifiers

NCT05945667

UN-1

Details and patient eligibility

About

The study is designed as a prospective parallel open label, two-arm, single center study exploring efficacy and safety of the use of the dietary supplement Uronext in women with cystitis in the acute stage. 120 otherwise healthy women with acute cystitis infection confirmed with the urine bacteriological examinations, aged 18-18 years, will be recruited. The distribution of patients will be done in 1:1 ratio. Control group will receive standard therapy, Monural (fosfomycin trometamol) 3 g, at the first day of the trial. The second group will also receive Monural (fosfomycin trometamol) 3 g, at the first day of the trial as well as Uronext food supplement, 1 time per day for the first 7 days. After the 7 day break, participants in the second group will follow supplementation scheme for the next 3 month.

Primary objective of the study is evaluation of the effectiveness of the dietary supplement Uronext in women with cystitis in the acute stage in the prevention of subsequent exacerbations of recurrent cystitis during 3 months of observation, measured as the number of relapses throughout the study period. Participnats will also fill in urination diary and questionnaires related to pain perception, quality of life and cystitis symptoms. Urine samples will be further examined at the follow up visits.

Safety will be evaluated based on reported adverse events, assessment of vital signs and laboratory evaluation.

Enrollment: 111 patients

Sex: Female

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women between the ages of 18 and 80.
• Patients who are able to fill out questionnaires, and wish to take part in the study.
• Cystitis in the acute stage.
• Informed consent to participate in the study.
• The patient's willingness and ability to fulfill the requirements of the protocol throughout the study.
• Consent of the patient and partner with preserved reproductive potential to use adequate methods of contraception (for example, a double barrier method) during the entire period of the study (including the period of follow-up).
• The presence of the gynecologist's conclusion obtained within 6 months before the patient's participation in the study about the absence of concomitant pathologies that can distort the results of the study.
• The presence of the results of bacteriological urine tests obtained within 7-10 days before the patient's participation in the study, pathogens of infections of the lower urinary tract. If the results of urine bacteriological examinations are not available, the results of urine culture tests performed at Visit 1 will be taken into account.

Exclusion criteria

• Patients with signs of upper urinary tract infection, such as temperature above 38°C, side/lower back pain, or soreness.
• Burdened allergic history.
• Hypersensitivity to any of the components that make up the investigational drugs.
• Patients with congenital anomalies in the development of genitourinary organs (exstrophy of the bladder, hypospadias, epispadias).
• Patients after undergoing surgical interventions on the organs of the genitourinary system.
• Patients who at the time of inclusion in the study noted: neurogenic dysfunction of the bladder, urinary incontinence, sclerosis of the neck of the bladder, urethral stricture, stone / stones of the bladder, bladder cancer, diverticula of the bladder, as well as other diseases of the genitourinary organs requiring specialized treatment.
• Any malignant neoplasm in the anamnesis.
• Unsatisfactory glycemic control (HbA1c ≥8%) in diabetes mellitus.
• Patients with uncontrolled infection as a result of exposure to human immunodeficiency virus (HIV) and/or active hepatitis.
• Patients with a history of drug or alcohol dependence within the last 5 years.
• Any clinically significant condition due to which, according to the researcher, the patient cannot take part in the study;
• Pregnancy, lactation, pregnancy planning during the study.
• Patients with any other serious or uncontrollable physical or mental condition/disease that the Researcher determines may put the patient at high risk of being removed from the study may disrupt or disprove the results of the study or likely prevent the patient from complying with the requirements of the study or completing the study.
• Participation in another clinical trial less than 6 months before the start of the study.
• Any other conditions that the researcher believes may indicate that the patient is not eligible to participate in the study.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

111 participants in 2 patient groups

Monural

Active Comparator group

Description:

3000 mg of fosfomycin trometamol per sachet

Treatment:

Drug: Monural

UroNext + Monural

Experimental group

Description:

3000 mg of fosfomycin trometamol per sachet 500 mg of Qcran, 2000 mg of D-mannose, 5 mcg of vitamin D3 per sachet

Treatment:

Drug: Monural

Dietary Supplement: UroNext